Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy.
The receptor for the type 1 insulin-like growth factor (IGF-1R) plays a critical role in the acquisition of the malignant phenotype. Using a highly metastatic murine lung carcinoma model, it was demonstrated that this receptor regulates several cellular functions that can impact on the metastatic potential of the cells, including cellular proliferation, anchorage-independent growth, cell migration, and invasion. The tumor model was used to develop several strategies for altering receptor expression and function as means of abrogating the metastatic potential of the cells. They include stable expression in the tumor cells of IGF-1R antisense RNA and dominant negative receptor mutants in which tyrosines in the kinase domain were substituted with phenylalanine. In addition, a novel strategy was used based on altering post ligand-binding receptor turnover. This led to inhibition of receptor re-expression and signaling and resulted in increased tumor cell apoptosis. When combined with the development of viral vectors designed to deliver genetic information with high efficiency, these strategies could form the basis for development of highly specific, antimetastatic therapy in tumors with known IGF-IR involvement.
Brodt
P
P
Department of Surgery, McGill University Health Center, Montreal, Quebec, Canada. pnina.brodt@muhc.mcgill.ca
Samani
A
A
Navab
R
R
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D009362:Neoplasm Metastasis / Q000503:physiopathology; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology
D000970:Antineoplastic Agents; D017526:Receptor, IGF Type 1